Connect
MJA
MJA

Comment on NATSEM’s report on the economic and societal cost of Alzheimer disease in Australia

Michael Valenzuela
Med J Aust 2022; 216 (10): . || doi: 10.5694/mja2.51521
Published online: 6 June 2022

To the Editor: The socio‐economic modelling of the impact of a hypothetical disease‐modifying treatment (DMT) for Alzheimer disease by the National Centre for Social and Economic Modelling (NATSEM)1 is an interesting contribution to what is a critical question for policymakers: how effective does a new antidementia treatment need to be to justify a given cost to the community?

  • Michael Valenzuela

  • Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney, Sydney, NSW


Correspondence: m.valenzuela@unsw.edu.au

Competing interests:

I am scientific co‐founder of Skin2Neuron, and have a financial interest in this biotech company that is developing a novel approach to treating Alzheimer disease. I was a paid senior consultant to the World Health Organization in the area of healthy ageing and cognition. I am the primary inventor of several patents related to a novel form of cell therapy with potential for application to Alzheimer disease and other neurological conditions.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.